Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Clinical trial NCT02332512 · UNKNOWN
Trial details
- NCT number
- NCT02332512
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-01
- Primary completion
- 2017-08-01
- Enrollment
- 417
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.